| Autor: |
Tadataka Takagi, Minako Nagai, Satoshi Nishiwada, Taichi Terai, Satoshi Yasuda, Yasuko Matsuo, Shunsuke Doi, Yuichiro Kohara, Masayuki Sho |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Annals of Gastroenterological Surgery, Vol 7, Iss 2, Pp 326-335 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2475-0328 |
| DOI: |
10.1002/ags3.12629 |
| Popis: |
Abstract Aim There is an urgent need to establish biomarkers for the treatment of pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to investigate the usefulness of the combined assessment of carbohydrate antigen 19‐9 (CA19‐9), carcinoembryonic antigen (CEA), and duke pancreatic monoclonal antigen type 2 (DUPAN‐2) in PDAC. Methods We retrospectively investigated the impact of three tumor markers on overall survival (OS) and recurrence‐free survival (RFS). Patients were classified into two groups: upfront surgery (US) and neoadjuvant chemoradiation (NACRT) groups. Results In total, 310 patients were evaluated. In the US group, patients who had all three elevated markers showed a significantly worse prognosis than the others (median: 16.4 months, P = .005). In the NACRT group, patients who had elevated CA 19‐9 and CEA levels after NACRT had significantly worse prognosis than the others (median: 26.2 months, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text